---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-054484"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2025-04-16T23:59:59+00:00"
generated_at: "2026-05-23T13:23:55.604966+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Akari Therapeutics FY2024 net loss $21.6M; cash runway into Sep 2025; new CEO named

## Summary
- FY2024 net loss from operations $21.6M vs $16.8M in 2023; R&D $7.0M, G&A $9.7M.
- Cash $2.6M at Dec 31, 2024; plus $6.6M private placement in March 2025 funds operations into Sep 2025.
- Lead ADC AKTX-101 (TROP2 PH1) for solid tumors; seeking licensing/strategic partner.
- Abizer Gaslightwala named President and CEO effective April 21, 2025.
- Merger with Peak Bio completed Nov 2024; pipeline focused on next-gen bifunctional ADCs.

## SEC filing metadata
- accession: 0000950170-25-054484
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2025-04-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000095017025054484/0000950170-25-054484-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000095017025054484/aktx-20250416.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-054484
- JSON: https://secwatch.observer/filing/0000950170-25-054484.json
- Plain text: https://secwatch.observer/filing/0000950170-25-054484.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.